CN109395099A - 一种提高结核菌素bcg-ppd皮试诊断试剂稳定性的方法 - Google Patents
一种提高结核菌素bcg-ppd皮试诊断试剂稳定性的方法 Download PDFInfo
- Publication number
- CN109395099A CN109395099A CN201811529499.XA CN201811529499A CN109395099A CN 109395099 A CN109395099 A CN 109395099A CN 201811529499 A CN201811529499 A CN 201811529499A CN 109395099 A CN109395099 A CN 109395099A
- Authority
- CN
- China
- Prior art keywords
- ppd
- bcg
- culture
- tween
- stoste
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 45
- 238000012360 testing method Methods 0.000 title claims abstract description 40
- 229960001005 tuberculin Drugs 0.000 title claims abstract description 33
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 26
- 229920000136 polysorbate Polymers 0.000 claims abstract description 23
- 238000002360 preparation method Methods 0.000 claims abstract description 16
- 241000894006 Bacteria Species 0.000 claims description 34
- WFJIVOKAWHGMBH-UHFFFAOYSA-N 4-hexylbenzene-1,3-diol Chemical compound CCCCCCC1=CC=C(O)C=C1O WFJIVOKAWHGMBH-UHFFFAOYSA-N 0.000 claims description 20
- 230000001376 precipitating effect Effects 0.000 claims description 20
- 239000007788 liquid Substances 0.000 claims description 19
- 238000001914 filtration Methods 0.000 claims description 14
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 14
- 238000011081 inoculation Methods 0.000 claims description 13
- 238000000502 dialysis Methods 0.000 claims description 12
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 12
- 229920000053 polysorbate 80 Polymers 0.000 claims description 12
- 230000037303 wrinkles Effects 0.000 claims description 10
- 244000061456 Solanum tuberosum Species 0.000 claims description 9
- 235000002595 Solanum tuberosum Nutrition 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 238000012549 training Methods 0.000 claims description 9
- 238000005516 engineering process Methods 0.000 claims description 8
- 230000001954 sterilising effect Effects 0.000 claims description 8
- 239000006185 dispersion Substances 0.000 claims description 7
- 238000004659 sterilization and disinfection Methods 0.000 claims description 6
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 5
- 238000012136 culture method Methods 0.000 claims description 5
- 238000004090 dissolution Methods 0.000 claims description 4
- 230000002779 inactivation Effects 0.000 claims description 4
- 238000011534 incubation Methods 0.000 claims description 4
- 238000000386 microscopy Methods 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 238000007865 diluting Methods 0.000 claims description 3
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 2
- 240000002114 Satureja hortensis Species 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 238000011161 development Methods 0.000 claims description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 2
- 229940113124 polysorbate 60 Drugs 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 11
- 238000001514 detection method Methods 0.000 abstract description 4
- 229960005486 vaccine Drugs 0.000 abstract description 3
- 230000035945 sensitivity Effects 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 238000001727 in vivo Methods 0.000 abstract 1
- 201000008827 tuberculosis Diseases 0.000 description 31
- 239000000243 solution Substances 0.000 description 25
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 229940070741 purified protein derivative of tuberculin Drugs 0.000 description 16
- 238000010790 dilution Methods 0.000 description 15
- 239000012895 dilution Substances 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 239000002609 medium Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000012856 packing Methods 0.000 description 7
- 238000002255 vaccination Methods 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000004108 freeze drying Methods 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 5
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 5
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 5
- 235000011130 ammonium sulphate Nutrition 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 239000000306 component Substances 0.000 description 5
- 238000003306 harvesting Methods 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 239000013049 sediment Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000003916 acid precipitation Methods 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 208000003643 Callosities Diseases 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 2
- 229910001626 barium chloride Inorganic materials 0.000 description 2
- 238000005842 biochemical reaction Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- OPCRGEVPIBLWAY-QNRZBPGKSA-N ethyl (2E,4Z)-deca-2,4-dienoate Chemical compound CCCCC\C=C/C=C/C(=O)OCC OPCRGEVPIBLWAY-QNRZBPGKSA-N 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- FDZZZRQASAIRJF-UHFFFAOYSA-M malachite green Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](C)C)C=C1 FDZZZRQASAIRJF-UHFFFAOYSA-M 0.000 description 2
- 229940107698 malachite green Drugs 0.000 description 2
- 238000011177 media preparation Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000012982 microporous membrane Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 208000009146 rhinoscleroma Diseases 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000221775 Hypocreales Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010022075 Injection site induration Diseases 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 208000036981 active tuberculosis Diseases 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 1
- 238000011225 antiretroviral therapy Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012297 crystallization seed Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 244000144992 flock Species 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000005297 pyrex Substances 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- FDRCDNZGSXJAFP-UHFFFAOYSA-M sodium chloroacetate Chemical compound [Na+].[O-]C(=O)CCl FDRCDNZGSXJAFP-UHFFFAOYSA-M 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0006—Skin tests, e.g. intradermal testing, test strips, delayed hypersensitivity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811529499.XA CN109395099B (zh) | 2018-12-13 | 2018-12-13 | 一种提高结核菌素bcg-ppd皮试诊断试剂稳定性的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811529499.XA CN109395099B (zh) | 2018-12-13 | 2018-12-13 | 一种提高结核菌素bcg-ppd皮试诊断试剂稳定性的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109395099A true CN109395099A (zh) | 2019-03-01 |
CN109395099B CN109395099B (zh) | 2020-02-21 |
Family
ID=65459205
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811529499.XA Active CN109395099B (zh) | 2018-12-13 | 2018-12-13 | 一种提高结核菌素bcg-ppd皮试诊断试剂稳定性的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109395099B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113444671A (zh) * | 2021-08-04 | 2021-09-28 | 成都可恩生物科技有限公司 | 一种可替代苏通马铃薯培养基的卡介菌菌种传代培养方法 |
CN114748615A (zh) * | 2022-04-29 | 2022-07-15 | 成都安永鼎业生物技术有限公司 | 一种治疗用重组卡介苗的冻干制剂及其制备方法和用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101732732A (zh) * | 2009-12-17 | 2010-06-16 | 中国兽医药品监察所 | 牛型结核菌素标准物质及其制备方法 |
CN103993065A (zh) * | 2014-05-07 | 2014-08-20 | 济宁医学院 | 一种结核分枝杆菌双相快速鉴别培养基及其应用 |
CN104237508A (zh) * | 2013-06-19 | 2014-12-24 | 华中农业大学 | 一种结核分枝杆菌的检测试剂盒及应用 |
-
2018
- 2018-12-13 CN CN201811529499.XA patent/CN109395099B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101732732A (zh) * | 2009-12-17 | 2010-06-16 | 中国兽医药品监察所 | 牛型结核菌素标准物质及其制备方法 |
CN104237508A (zh) * | 2013-06-19 | 2014-12-24 | 华中农业大学 | 一种结核分枝杆菌的检测试剂盒及应用 |
CN103993065A (zh) * | 2014-05-07 | 2014-08-20 | 济宁医学院 | 一种结核分枝杆菌双相快速鉴别培养基及其应用 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113444671A (zh) * | 2021-08-04 | 2021-09-28 | 成都可恩生物科技有限公司 | 一种可替代苏通马铃薯培养基的卡介菌菌种传代培养方法 |
CN114748615A (zh) * | 2022-04-29 | 2022-07-15 | 成都安永鼎业生物技术有限公司 | 一种治疗用重组卡介苗的冻干制剂及其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
CN109395099B (zh) | 2020-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Avery et al. | Acute lobar pneumonia | |
Felix | A new type of typhoid and paratyphoid vaccine | |
CN108430500A (zh) | 用于针对肠外致病性大肠杆菌的免疫保护的方法和组合物 | |
Gordon | Studies of the viruses of vaccinia and variola | |
CN102917730A (zh) | 修饰的脑膜炎球菌fHBP多肽 | |
CN109182167A (zh) | 一种高效价结核菌素皮试诊断试剂(ppd)生产工艺 | |
Cecil et al. | Bacteriology of the blood and joints in rheumatic fever | |
CN103849632A (zh) | 鸡传染性支气管炎弱毒株s1基因及其弱毒株和应用 | |
CN109395099A (zh) | 一种提高结核菌素bcg-ppd皮试诊断试剂稳定性的方法 | |
CN103721249B (zh) | 一种流脑疫苗及其制备方法 | |
CN104069489B (zh) | 鸡新城疫和传染性法氏囊二联灭活疫苗及其制备方法 | |
CN108619507A (zh) | 呼吸道合胞病毒-流脑联合疫苗及其制备方法 | |
Felix et al. | The preparation of anti-typhoid serum in the horse for therapeutic use in man | |
Mishulow et al. | Protection of Mice Against H. Pertussis by Serum. Comparison of Protection with Agglutination: Preliminary Paper | |
RU2206337C1 (ru) | Лекарственный препарат для лечения мышечных дистоний и способ его получения | |
Schultz et al. | Studies on the Antigenic Properties of the Ultraviruses: VII. Nature of the Viricidal Antibody in Antipoliomyelitis Serum | |
Griffiths et al. | Freeze-dried BCG | |
CN109745548A (zh) | 一种百日咳毒素在治疗脑梗死中的应用 | |
Fairbrother | Handbook of filterable viruses | |
Margolis et al. | Bacteriology of the blood in chronic infectious arthritis | |
CN102584993A (zh) | 一种高效价人破伤风免疫血浆及其制备工艺 | |
RU2422832C1 (ru) | Способ получения эритроцитарного антигенного гистоплазмозного и кокцидиоидомикозного диагностикума | |
Eisenberg | Principles of bacteriology | |
CN105418759B (zh) | 一种抗内氏放线菌卵黄抗体及其制备方法 | |
Citron | Immunity, Methods of Diagnosis and Therapy and Their Practical Application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 101407 No.17, Yanqi North 3rd Street, Yanqi Economic Development Zone, Huairou District, Beijing Patentee after: Beijing Xiangrui Biological Products Co.,Ltd. Address before: 101407 No.17, Yanqi North 3rd Street, Yanqi Economic Development Zone, Huairou District, Beijing Patentee before: BEIJING SANROAD BIOLOGICAL PRODUCTS CO.,LTD. |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 101407 No.17, Yanqi North 3rd Street, Yanqi Economic Development Zone, Huairou District, Beijing Patentee after: Beijing Xiansheng Xiangrui Biological Products Co.,Ltd. Address before: 101407 No.17, Yanqi North 3rd Street, Yanqi Economic Development Zone, Huairou District, Beijing Patentee before: Beijing Xiangrui Biological Products Co.,Ltd. |